A Phase II Study of Erlotinib With Bevacizumab in Chemotherapy Naive Performance Status (PS) 2 Patients With Advanced Non-Small Cell Lung Cancer.
Phase of Trial: Phase II
Latest Information Update: 15 Feb 2016
At a glance
- Drugs Bevacizumab (Primary) ; Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 05 May 2009 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.
- 05 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 Apr 2009 Additional lead trial investigator 'Patel JD' identified as reported by Robert H. Lurie Comprehensive Cancer Center, Northwestern University.